#Obesity medicine
Chronic weight management as a clinical specialty.
How semaglutide produces weight loss
Semaglutide works mainly in the brain, suppressing appetite via GLP-1 signalling. Here is what the STEP trials found and what stops when the drug stops.
Tirzepatide in youth: first real-world data
A study of 74 youth prescribed tirzepatide at three clinics found lower blood sugar and BMI. What can the first real-world numbers actually show?
Tirzepatide vs carpal tunnel: a 2026 study
A 2026 cohort study found tirzepatide users had lower rates of carpal tunnel syndrome than users of other GLP-1 or anti-obesity drugs.
Tirzepatide: 10-year CVD risk in SURMOUNT-1
Post-hoc SURMOUNT-1 analysis: tirzepatide 15 mg cut predicted 10-year CVD risk by 1.92 pp at 72 weeks, widening to a 5.15 pp gap over placebo at three years.
Peru obesity drugs: budget impact explained
A 2026 analysis of 76,819 Peruvians found that full obesity drug coverage could cost up to S/143 billion per year. Here is what the numbers mean.
Oral GLP-1 drugs for obesity, no diabetes
A 2026 network meta-analysis of nine trials ranks oral semaglutide and orforglipron as top performers for weight loss in adults with obesity without diabetes.
Retatrutide: US compassionate use explained
Retatrutide is investigational. The US has opened a compassionate use pathway after Trump speculation. Here is what that means and who may qualify.
Zepbound versus obesity pills
Zepbound still has strong direct trial evidence as oral obesity medicines add useful, but not automatically superior, options.
Tirzepatide for sleep apnea
Tirzepatide reduced sleep-apnea severity in adults with obesity, but the evidence does not make it a universal substitute for CPAP.
Semaglutide meta-analysis: what it adds
A 2026 pooled analysis of four semaglutide trials in non-diabetic obesity lands on almost exactly the number STEP 1 reported in 2021.
GLP-1 and mood drugs: reading the signal
A 2026 Australian study links GLP-1 starts to fewer antidepressant starts. The design behind it decides how much that finding is worth.
Does Retatrutide cause muscle loss?
Phase 2 DXA data shows fat mass declining far more than lean mass, with lean loss proportional to other obesity treatments.